GenSight Biologics begins treating ND4-LHON patients under France's AAC compassionate access program. Analyse what REVISE and AAC mean for the regulatory pathway.
Novartis acquires SNV4818, a next-gen mutant-selective PI3Ka inhibitor, for up to $3bn. What this means for the HR+/HER2- breast cancer market. Read now.
Aptar's UDS Powder system enters ENA Respiratory's POSITS Phase II trial. Analyse what INNA-051 must prove in 2026 and why the device choice matters. Read more.
KalVista's sebetralstat pediatric trial data heads to Madrid. What it means for the HAE on-demand market and a 2026 FDA filing. Read the analysis.
IntraBio files the first-ever FDA application for an A-T therapy. Analyse the Phase III evidence, regulatory pathway, and what approval would mean.
Curi Bio and Battelle partner to commercialise a human NMJ assay for botulinum toxin potency testing. What this changes for NAM adoption and the mouse bioassay. Read more.
ImmunityBio's first Asia approval for ANKTIVA in BCG-unresponsive bladder cancer: what the Macau clearance means for its global strategy. Read the analysis.
Cleerly's INVICTUS registry shows AI-QCT matches IVUS in coronary plaque quantification. Read the clinical analysis.
Nivolumab wins U.S. frontline and EU relapsed cHL approvals. Analyse what the dual verdict means for sequencing, safety, and reimbursement.
Incyte presents 54-week STOP-HS phase 3 data for povorcitinib at AAD 2026. Analyst review of durability, safety, and what the dataset means for the NDA.